Biogen recently shared that they have completed enrollment in the global DEVOTE and RESPOND clinical studies. Check out the full SMA Community Statement here.
Biogen Shares DEVOTE and RESPOND Study Updates Read More »
Last week, Genentech, a member of the Roche Group, presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic SMA, aged from birth to 6 weeks. These data were presented at the 28th World Muscle Society (WMS) Congress. Read more about
Genentech Shares 1-Year Primary Analysis from RAINBOWFISH Read More »
Dear SMA Community, It was a pleasure to be able to join so many of you at the Cure SMA Annual Conference in Orlando this year, and we look forward to seeing some of you again at the Cure SMA Chapter and Leadership Meeting. In this community update we are pleased to share a Plain
Novartis Gene Therapies SMA Community Update Read More »
Hey, it’s Allie here from Oklahoma! I am privileged to serve on the Cure SMA Adult Advisory Council and am part of a group of adults and family members with SMA who are in Washington, D.C. to help advocate for the SMA community. On Thursday, our group of SMA community leaders from across the country
Cure SMA on Capitol Hill – A Message from Allie Williams Read More »
Dear SMA Community, As we reflect on SMA Awareness Month, we take this opportunity to celebrate all those who are a part of the SMA community and the future we’re building together. We are grateful for those living with SMA and loved ones who share their experiences with others and help inspire our work, the
SMA Highlights and Updates from Biogen Read More »
